<DOC>
	<DOC>NCT01760564</DOC>
	<brief_summary>To evaluate the changes in cognitive function after miglustat treatment in Niemann-Pick type C patients.</brief_summary>
	<brief_title>Application of Miglustat in Patients With Niemann-Pick Type C</brief_title>
	<detailed_description>Patients with Niemann-Pick C disease will be treated with Miglutat 200mg tid. Neurologic evaluation and safety will be monitored periodically.</detailed_description>
	<mesh_term>Pick Disease of the Brain</mesh_term>
	<mesh_term>Aphasia, Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease, Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease, Type C</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Confirm diagnosis of NiemannPick C disease Symptomatic including motor or mental symptoms Unknown severe diarrhea for more than 7 day Allergy to miglustat</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Niemann-Pick disease type C</keyword>
	<keyword>miglustat</keyword>
</DOC>